Top 50 Biotech Startup Investors in Germany (August 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
HTGF (High-Tech Gruenderfonds)
VC Fund
|
54 | Germany, Switzerland, United States | Seed, Series A | Software, Biotechnology, Information Technology | $909k–$39M |
|
Bayern Kapital
VC Fund
|
20 | Germany, United States, Finland | Seed, Series A | Software, Health Care, Information Technology | $1.1M–$32M |
|
Boehringer Ingelheim Venture Fund
VC Fund
|
19 | United States, Germany, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $1.8M–$50M |
|
KfW
VC Fund
|
16 | Germany, India, United Kingdom | Series A, Series B | Biotechnology, Software, Health Care | $2.2M–$17M |
|
MIG Capital
VC Fund
|
16 | Germany, France, Austria | Series A, Series B | Biotechnology, Health Care, Software | $1.6M–$60M |
|
NRW.BANK
VC Fund
|
16 | Germany, United States, France | Seed, Series A, Series B | Information Technology, Software, Biotechnology | $219k–$71M |
|
IFB Innovationsstarter
VC Fund
|
10 | Germany, United States | Seed, Grant | Software, SaaS, Artificial Intelligence | $79k–$3M |
|
TGFS - Technologiegründerfonds Sachsen
VC Fund
|
10 | Germany, United States | Seed, Series A | Software, Information Technology, Manufacturing | $932k–$15M |
|
Wellington Partners
VC Fund
|
9 | Germany, United States, United Kingdom | Series A, Series B | Health Care, Biotechnology, Medical | $3.1M–$60M |
|
b.value AG
VC Fund
|
9 | Germany, Poland | Seed, Series A | Biotechnology, Manufacturing, Chemical | $541k–$39M |
|
BioMedPartners
VC Fund
|
9 | Switzerland, Germany, France | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $4.9M–$75M |
|
EQT Ventures
VC Fund
|
8 | Sweden, Germany, United States | Series A, Seed, Series B | Software, Artificial Intelligence, Information Technology | $2.6M–$100M |
|
IBB Ventures
VC Fund
|
7 | Germany, United States, United Kingdom | Seed, Series A | Software, Health Care, SaaS | $1M–$11M |
|
Techno Venture Management
VC Fund
|
7 | United States, Germany, United Kingdom | Series B, Series A | Biotechnology, Health Care, Pharmaceutical | $4.7M–$44M |
|
coparion
VC Fund
|
6 | Germany, Switzerland, United States | Series A, Seed, Series B | Software, SaaS, FinTech | |
|
Entrepreneurs First
VC Fund
|
6 | United Kingdom, United States, India | Pre-Seed, Seed, Series A | Artificial Intelligence, Software, Information Technology | $55k–$45M |
|
eCAPITAL ENTREPRENEURIAL PARTNERS
VC Fund
|
6 | Germany, United States, Italy | Series A, Series B | Information Technology, Software, Manufacturing | $2.7M–$27M |
|
bmp Ventures
VC Fund
|
6 | Germany, United States, Austria | Seed, Series A | Software, Information Technology, Manufacturing | $30k–$5.9M |
|
Forbion Capital Partners
VC Fund
|
6 | United States, United Kingdom, The Netherlands | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $16M–$180M |
|
Good Seed Ventures
VC Fund
|
6 | Germany, Israel, United States | Seed, Series A, Pre-Seed | Food and Beverage, Food Processing, Biotechnology | $25k–$50M |
|
bm-t beteiligungsmanagement thuringen
VC Fund
|
6 | Germany, United States | Seed, Series A | Software, Health Care, Information Technology | $461k–$10M |
|
EMBL Ventures
VC Fund
|
5 | Germany, Austria, Ireland | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $3.9M–$70M |
|
GENIUS Venture Capital
VC Fund
|
5 | Germany, Spain | Seed, Pre-Seed | Software, Logistics, Health Care | $509k–$7.1M |
|
DvH Ventures
VC Fund
|
5 | Germany, Austria, United Kingdom | Seed, Series A | Health Care, Software, Financial Services | $1.2M–$31M |
|
Brandenburg Kapital
VC Fund
|
5 | Germany, United Kingdom | Seed, Series A | Health Care, Software, Information Technology | $823k–$13M |
|
Simon Capital
VC Fund
|
5 | Germany, Austria, The Netherlands | Series A, Seed, Series B | Software, Biotechnology, Food and Beverage | $1.7M–$57M |
|
BayBG Venture Capital
VC Fund
|
5 | Germany, Italy, United States | Series A, Series B | Software, Information Technology, Health Care | $428k–$21M |
|
Seventure Partners
VC Fund
|
5 | France, United States, Germany | Series A, Series B | Biotechnology, Health Care, Software | $3.3M–$63M |
|
Andera Partners
VC Fund
|
4 | France, United States, Germany | Series B, Private Equity, Series A | Biotechnology, Health Care, Medical | $7M–$237M |
|
S-Venture Capital Dortmund
VC Fund
|
4 | Germany | Series B, Series A | Biotechnology, Guides, Genetics | $3.6M–$9M |
|
Amino Collective
VC Fund
|
4 | United States, United Kingdom, Germany | Seed, Series A, Pre-Seed | Biotechnology, Health Care, Artificial Intelligence | $125k–$37M |
|
BlueYard Capital
VC Fund
|
4 | United States, Germany, United Kingdom | Seed, Series A, Pre-Seed | Software, Biotechnology, Blockchain | $200k–$47M |
|
Happiness Capital
VC Fund
|
4 | Germany, United States, United Kingdom | Series A, Seed, Series B | Biotechnology, Food and Beverage, Life Science | $2M–$61M |
|
Grazia Equity
VC Fund
|
4 | Germany, United States, Switzerland | Series A, Series B, Seed | Internet, E-Commerce, Biotechnology | $1.1M–$59M |
|
Cascara Ventures
VC Fund
|
4 | Germany, Finland, The Netherlands | Series A, Seed, Series B | Health Care, Medical Device, Medical | |
|
EIC Fund
VC Fund
|
4 | Germany, The Netherlands, Austria | Pre-Seed, Seed | Biotechnology, Health Care, Information Technology | |
|
Possible Ventures
VC Fund
|
4 | Germany, United States, Australia | Seed, Pre-Seed, Series A | Software, Biotechnology, Information Technology | $586k–$47M |
|
German Federal Ministry of Research, Technology and Space
VC Fund
|
4 | Germany, United States, Canada | Grant, Seed, Series B | Biotechnology, Medical, Health Care | $294k–$11M |
|
Seed Fonds Aachen
VC Fund
|
4 | Germany | Seed, Series A | Biotechnology, Medical, Health Care | $2.2M–$6M |
|
LSP BioVentures
VC Fund
|
4 | United States, Germany, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $5.3M–$194M |
|
Creathor Ventures
VC Fund
|
4 | Germany, Switzerland, United States | Series A, Series B | Software, Health Care, Biotechnology | $2M–$30M |
|
better ventures
VC Fund
|
4 | Germany, Switzerland | Pre-Seed, Seed, Series A | Software, Food and Beverage, E-Commerce | $1.1M–$6.9M |
|
Delivery Hero Ventures
VC Fund
|
3 | Singapore, Egypt, Brazil | Series A, Seed, Series B | E-Commerce, Information Technology, Food Delivery | |
|
ERP Startfonds
VC Fund
|
3 | Germany, United States | Series B, Series A | Biotechnology, Pharmaceutical, Apps | |
|
Think.Health
VC Fund
|
3 | Germany, United States, France | Seed, Series A, Series B | Health Care, Biotechnology, Medical Device | $1.1M–$28M |
|
TVM Capital
VC Fund
|
3 | United States, Germany, United Kingdom | Series B, Series C | Biotechnology, Health Care, Pharmaceutical | $7.5M–$55M |
|
Global Asset Fund
VC Fund
|
3 | Germany | Series A, Series B | Medical, Therapeutics, Biotechnology | $1M–$2.9M |
|
Lima Ventures
VC Fund
|
3 | Turkey, United Kingdom, Estonia | Seed, Pre-Seed | Artificial Intelligence, Software, FinTech | |
|
TechVision Fund
VC Fund
|
3 | Germany, Spain | Seed, Series A, Pre-Seed | Software, Health Care, Manufacturing | |
|
Ananda Impact Ventures
VC Fund
|
3 | Germany, United Kingdom, Finland | Seed, Series A | Health Care, Software, Information Technology | |
| Access all 979 investors in Germany Biotech startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
High-Tech Grunderfonds finances startups with growth potential. Its team of investment managers supports young companies with expertise, entrepreneurial spirit, and passion. The company focuses in the fields of digital tech, industrial tech, life sciences, chemistry, and related business areas. It also focuses on financial services in varioussectors.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Series A
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 610
- Round size: Seed $909k–$7M; Series A $3.5M–$39M
- Lead/follow: 34% lead, 66% follow
- Last fund: Likely still investing — raised $522M in 2022
Portfolio highlights
- CorTec — Reliable products for active implantable device development. We realize your next project with you and offer individual solutions that meet your specific requirements for Medical Devices, especially in neurotechnology.
- Coinlend — Coinlend - The Lending-Bot for Bitfinex & Liquid Genearate interest from your Bitcoin and Altcoin investments!
- CenterPoint - Connective Software Engineering — CenterPoint was founded in 2000 and is based in Villach, Austria with an additional office in Warsaw, Poland. CenterPoint - Connective Software Engineering develops and markets process control and fault detection and classification software solutions. The company offers cause effect analysis, metrology assessment, and close loop and run to runcontrol services. It's focus are the semiconductors, electronics, and steel and alloy industries.
Bayern Kapital (founded at the end of 1995) is a wholly owned subsidiary of the LfA Foerderbank Bayern (Bavaria‘s development bank). Bayern Kapital’s objective is to finance research and development as well as the market launch of new products, product diversifications, and expansion of the market share.The requesting company has to be located inBavaria. Industries are e. g. IT/software, life sciences, new materials, micro-systems and environmental technologies.Bayern Kapital and its funds have invested in more than 250 companies and currently manages funds to the value of EUR 340 m. The five investing funds currently managed by Bayern Kapital are Seedfonds Bayern, Clusterfonds Start-Up!, Innovationsfonds, Innovationsfonds EFRE and Wachstumsfonds Bayern.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Seed, Series A
- Geography: Germany, United States, Finland
Investor stats
- Total investments: 249
- Round size: Seed $1.1M–$5.9M; Series A $4.4M–$32M
- Lead/follow: 14% lead, 86% follow
- Last fund: May invest from a new fund soon — raised $26M in 2010
Portfolio highlights
- Hema.to — Hema.to provides fully automated, AI-powered blood cancer detection suggestions based on flow cytometry data.
- 4.screen — The Driver Interaction Platform. Connect with drivers in real-time to deliver personalized and targeted campaigns.
- inContAlert — inContAlert is a deep tech start-up disrupting the field of incontinence. The technology of inContAlert helps people with bladder dysfunction to monitor the filling level of their urinary bladder.inContAlert, therefore, developed an mHealth device, which collects and analyzes data with the help of deep learning algorithms. The information is thendisplayed on an app and sends an alert to incontinence patients when a predefined filling level is reached. inContAlert thereby minimizes the risk of an uncontrolled loss of urine or the harmful distension of the bladder. With the help of inContAlert, incontinence patients can go back to normal and live a carefree life.
Discover Boehringer Ingelheim Venture Fund. We invest in groundbreaking science to transform care. Explore our mission and join us in advancing medicine
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, Germany, Switzerland
Investor stats
- Total investments: 104
- Round size: Seed $1.8M–$20M; Series A $3.8M–$34M; Series B $11M–$50M
- Lead/follow: 47% lead, 53% follow
- Last fund: May invest from a new fund soon — raised $250M in 2018
Portfolio highlights
- Tacalyx — Tacalyx develops therapeutics targeting cancer-specific carbohydrate antigens on the surface of metastatic malignant tumors where no satisfactory treatments exist.The name Tacalyx is derived from TACA (Tumor Associated Carbohydrate Antigen) and ‘lyx’ from the term Glycocalyx, the glycan-containing layer covering cells. Cancer cells differ fromnormal cells by displaying aberrant carbohydrate structures on their surfaces promoting metastasis, angiogenesis or suppression of the immune system. TACAs result from the aberrant glycosylation that is seen with transformation to a tumor cell and represent attractive targets for cancer treatment since they are displayed with high cancer specificity and enhance tumor virulence via the mentioned diverse mechanisms.
- smartbax — We develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.
- Rinri Therapeutics — Rinri Therapeutics has been founded on pioneering research into auditory stem cells led by Professor Marcelo Rivolta at the University of Sheffield.
KfW gives impetus to economic, social and ecological development worldwide. As a promotional bank under the ownership of the Federal Republic and the Länder (federal states), it offers support to encourage sustainable improvement in economic, social, ecological living and business conditions, among others in the areas of small and medium-sizedenterprise, entrepreneurialship, environmental protection, housing, infrastructure, education finance, project and export finance, and development cooperation.
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Series A, Series B
- Geography: Germany, India, United Kingdom
Investor stats
- Total investments: 160
- Round size: Series A $2.2M–$7.7M; Series B $3.3M–$17M
- Lead/follow: 16% lead, 84% follow
Portfolio highlights
- Andercore — Andercore connects global suppliers and local buyers on one AI-driven platform, automating inventory selection, pricing, quotes, financing and global distribution at scale.
- AtlasEdge — Empowering a sustainable digital society by enabling infrastructure where it is needed.
- Quantum Systems — Our vision is to become the global leader in providing aerial data for decision making by the use of our drones.
MIG Capital is one of the leading German VC Investors. We invest in European Deep Tech and Life Sciences from early to late stage (Seed, Series A, and beyond). We use investments to shape a better tomorrow, today. Our team currently manages 17 MIG public venture capital funds regulated by BaFin, the German financial markets authority. These fundsoperate with more than EUR 1.2 billion capital committed by >60,000 private investors across Germany and Austria.Today, our portfolio consists of 30 companies.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Series A, Series B
- Geography: Germany, France, Austria
Investor stats
- Total investments: 97
- Round size: Series A $2.2M–$40M; Series B $1.6M–$60M
- Lead/follow: 44% lead, 56% follow
- Last fund: May invest from a new fund soon — raised $70M in 2014
Portfolio highlights
- NcodiN — The High Performance Computing (HPC) and ArtificiaI Intelligence (AI) era requires unprecedented computing capabilities. With this in view, industry is heading towards zettascale supercomputers, based on >100k processing units. Chiplets-based disaggregated processors and memory-centric computing architectures are taking over and require an ever more intensive communication between dies. Thus, today interconnect bottleneck is the main
- GlassPoint Solar — GlassPoint provides solar steam generators to the oil and gas industry for applications such as Enhanced Oil Recovery. It replaces gas-fired steam generation with solar, GlassPoint can reduce EOR gas consumption by up to 80 percent. The company was founded in 2008 and headquartered in Fremont, California.
- Zadient Technologies — Zadient produces semiconductor manufacturing materials that are critical for the entire silicon carbide (SiC) value chain
NRW.BANK is the development bank for the state of North Rhine-Westphalia. It supports its owner – the state of North Rhine-Westphalia – in fulfilling its tasks, notably in the fields of structural, economic, social and housing policy. NRW.BANK pools the promotion and development programmes of the state of North Rhine-Westphalia, the FederalRepublic of Germany and the European Union and combines them with its own equity and debt products and advisory services. It offers the full range of financial products in three areas “Economy”, “Housing”, and “Infrastructure/Municipalities”. NRW.BANK operates in a competitively neutral manner as a partner of banks and savings banks.
Show more...Investment focus
- Industry: Information Technology, Software, Biotechnology
- Stage:Seed, Series A, Series B
- Geography: Germany, United States, France
Investor stats
- Total investments: 131
- Round size: Seed $219k–$7.7M; Series A $3.8M–$36M; Series B $3.8M–$71M
- Lead/follow: 21% lead, 79% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- ENTRYZERO — ENTRYZERO is a cybersecurity startup that develops an AI-powered software platform specializing in Threat Exposure Management,the company helps organizations continuously monitor their digital attack surface from a hacker’s perspective to identify and mitigatevulnerabilities automatically.
- OMMM — OMMM Operations Management Solutions is a software house that specializes in the digitization and automation of industrial planning.
- Nuclidium — NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics. Using copper isotopes, Copper-61 for diagnostics and Copper-67 for therapeutics, the company is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics.
The IFB Innovationsstarter is an innovation funding and investment company of the City of Hamburg providing grants and investments.
Show more...Investment focus
- Industry: Software, SaaS, Artificial Intelligence
- Stage:Seed, Grant
- Geography: Germany, United States
Investor stats
- Total investments: 90
- Round size: Seed $365k–$3M; Grant $79k–$177k
- Lead/follow: 39% lead, 61% follow
Portfolio highlights
- mo:re GmbH — We offer standardized tissue cultures and protocols to better predict drug responses and investigate disease models.
- Atrya — Atrya develops regulatory-compliant blockchain payments for international companies.
- DEALCIRCLE — DealCircle is a digital M&A solution and partner of hundreds of M&A advisors. We support in identifying buyers and addressing the market. This provides investors access to a comprehensive deal flow of relevant projects.
TGFS - Technologiegruenderfonds Sachsen is an early stage VC fund targeting high tech startups with strong growth potential. The fund invests into ventures located in Saxony/Germany, Europe's leading semiconductor cluster. The team has invested into more than 120 companies so far, including more than 40 investments from the currentfund.
Show more...Investment focus
- Industry: Software, Information Technology, Manufacturing
- Stage:Seed, Series A
- Geography: Germany, United States
Investor stats
- Total investments: 158
- Round size: Seed $932k–$6M; Series A $1.9M–$15M
- Lead/follow: 23% lead, 77% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Prodlane — Prodlane, the company behind MAIA, is a technology company based in Leipzig that specializes in intelligent software solutions for SMEs in the DACH region. With MAIA, we are setting new standards in data analysis and daily knowledge management in all areas of the company using AI, thereby driving forward the digital transformation of SMEs.
- Cyber Insight — Cyber Insight - Measure, Manage, Mitigate Cyber Risks
- HandsOn Robotics — Handson Robotics provides state of the art robotics automation workflows for commercial kitchens.
Wellington Partners is a venture capital firm that invests in technology and life sciences companies, focusing on Digital Media, Software, Electronics & Photonics, Resource Efficiency, and Biotech/Life Sciences. It is committed to providing outstanding entrepreneurs with the necessary resources to fund their strategies. We typically leadfinancing rounds ranging from € 0.5 million to € 20 million. Depending on the maturity of the company, its own commitment can go as high as € 15 million.Wellington was established in 1998 and has offices in Munich, London, and Zurich.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B
- Geography: Germany, United States, United Kingdom
Investor stats
- Total investments: 201
- Round size: Series A $3.1M–$36M; Series B $8.3M–$60M
- Lead/follow: 30% lead, 70% follow
- Last fund: May invest from a new fund soon — raised $222M in 2019
Portfolio highlights
- nyra health — nyra health is an artificial intelligence and evidence-based neurological research tablet app that offers a revolutionary form of therapy. nyra health was founded in 2020 and was headquartered in Vienna, Austria.
- Nuclidium — NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics. Using copper isotopes, Copper-61 for diagnostics and Copper-67 for therapeutics, the company is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics.
- Beren Therapeutics — Founded to serve patients through transformative medicines
b.value AG are into Biotechnology investments.
Show more...Investment focus
- Industry: Biotechnology, Manufacturing, Chemical
- Stage:Seed, Series A
- Geography: Germany, Poland
Investor stats
- Total investments: 14
- Round size: Seed $541k–$2.5M; Series A $3M–$39M
- Lead/follow: 14% lead, 86% follow
Portfolio highlights
- PL BioScience — STEM CELL EXPANSION IN SAFE AND REPRODUCIBLE CONDITIONS. We deliver advanced 2D and 3D cell culture solutions based on human Platelet Lysate – for basic research, cellular therapeutics and clinical applications. Choose between different safety grades meeting your needs: Research Grade, GMP Grade or GMP-Clinical Grade.
- Cultimate Foods — At Cultimate, we are transforming the flavor and aroma industry with natural innovative ingredients.
- traceless materials — traceless materials offer a holistically sustainable alternative to plastics: 100% biobased on plant residues, compostable under natural conditions, and free of toxic chemicals. For a future free of pollution and waste!
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: Switzerland, Germany, France
Investor stats
- Total investments: 88
- Round size: Series A $5.3M–$31M; Series B $4.9M–$75M; Series C $5.8M–$47M
- Lead/follow: 34% lead, 66% follow
- Last fund: May invest from a new fund soon — raised $113M in 2018
Portfolio highlights
- T-CURX — T-CURX develops a new generation of T cells for personalized cancer immunotherapy, built on a proprietary platform that overcome challenges ...
- iDEL Therapeutics — iDEL Therapeutics is advancing a new class of cancer medicines by delivering therapeutic payloads directly into the cytosol of tumor cells through a unique, pan-cancer uptake mechanism.
- ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
EQT Ventures is a European VC fund with just over €2.3 billion in total capital raised. EQT Ventures I launched in May 2016, with commitments totaling €566 million and a simple mission - to be the kind of VC the team would have liked to have had on their own startup journeys. Recognizing that building and growing a company takes more than justcapital, the EQT Ventures team provides founders with support and advice throughout different stages of growth. EQT Ventures doesn't focus on particular markets or industries, but on bold and ambitious founders who have the grit and determination to build global success stories. EQT Ventures II launched in November 2019, with commitments totaling €660 million. EQT Ventures III launched in 2022, with commitments totaling €1.1 billion, making it the biggest European Venture Capital fund committed to early-stage tech startups. The EQT Ventures team is based across six offices in London, Stockholm, Berlin, Paris, Amsterdam, Paris, and San Francisco, taking a locals-with-locals approach and supporting founders on the ground. Motherbrain, EQT Ventures' in-house-developed artificial intelligence (AI) platform, ensures the team has a data-driven approach and has driven more than $100 million in portfolio company investments.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Series A, Seed, Series B
- Geography: Sweden, Germany, United States
Investor stats
- Total investments: 273
- Round size: Seed $2.6M–$15M; Series A $6.8M–$44M; Series B $18M–$100M
- Lead/follow: 55% lead, 45% follow
- Last fund: Likely still investing — raised $1.1B in 2022
Portfolio highlights
- CallDesk — Transform your contact center with 24/7 AI voice agents. From day one, get custom setup, rapid deployment, and reliable integrations for smoother customer journeys.
- Peltarion — With our AI platform, you can build your own deep learning models and benefit from the smart things with real-world use of artificial intelligence
- CodeSandbox — CodeSandbox is a cloud development platform that empowers developers to code, collaborate and ship projects of any size from any device in record time.
Pre-Seed to Series A for Berlin-based founders. Where 30 years of expertise, capital and execution power meet.
Show more...Investment focus
- Industry: Software, Health Care, SaaS
- Stage:Seed, Series A
- Geography: Germany, United States, United Kingdom
Investor stats
- Total investments: 243
- Round size: Seed $1M–$4.6M; Series A $2.3M–$11M
- Lead/follow: 20% lead, 80% follow
- Last fund: Likely still investing — raised $33M in 2022
Portfolio highlights
- Nenna AI — Nenna AI is a powerful AI enablement platform designed for the secure application of AI technologies.
- Jurafuchs — Jurafuchs provides legal education via a mobile app.
- dsb Deutsche Sanierungsberatung — dsb Deutsche Sanierungsberatung provides easy and sustainable solutions for climate-friendly homes energy-efficient renovations for homeowners.
Techno Venture Management is a venture capital and private equity firm focused on healthcare industry.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series B, Series A
- Geography: United States, Germany, United Kingdom
Investor stats
- Total investments: 99
- Round size: Series A $4.7M–$22M; Series B $5.2M–$44M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Streaming21 — Streaming21 is a solution provider of seamless on-demand and IP broadcasting service platform for connected digital home.
- Helomics — Helomics® is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a personalized comprehensive tumor profile utilizing a proprietary set of laboratory platforms that leverage both tissue-based live and fixed cellular basedanalysis allowing physicians to characterize malignant tumors on a personalized basis. Helomics’ novel molecular and cellular markers and bioinformatics services support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer.
- Precision Therapeutics — Precision Therapeutics is a pharmaceutical research and development business that develops personalized cancer treatments for patients.
Coparion provides venture capital to accelerate momentum and growth. With a currently active fund of EUR 275 million, Coparion has the means to do so.Coparion supports entrepreneurial vision with know-how, but without intervening in daily business operations. Thanks to in-depth experience in venture capital and in building companies, the Coparionteam discerns potential and opens up new perspectives. Coparion has the substance, tenacity, and creativity required to mutually manage difficult situations successfully.Coparion only invests with co-investors. The fund invests up to EUR 15M per company, usually in several financing rounds of EUR 0.5-8M each. The investment focus is on German companies in the start-up and early growth phases. Coparion is based in Cologne and Berlin.
Show more...Investment focus
- Industry: Software, SaaS, FinTech
- Stage:Series A, Seed, Series B
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 97
- Lead/follow: no public data
Portfolio highlights
- Finoa — Finoa is the leading European crypto-asset management platform, empowering businesses and institutions to engage with crypto safely and intuitively.
- Protembis — ProtEmbo is designed to be a simple and reliable solution for one of the most feared complications during TAVR.The advent of transcatheter treatments for valvular heart disease has been a major revolution in the care of patients with disabilities or intercurrent illnesses that precluded undergoing stressful open cardiac surgical procedures.Nonetheless, in spite of ongoing improvements in TAVR procedures and outcomes, the occurrence of cerebrovascular events represents a significant morbidity of TAVR.Protembis was founded based on the vision to reduce the risk of cerebrovascular events, thereby improving outcomes and making TAVR even safer – especially in light of TAVR shifting to younger and lower-risk patients. The ProtEmbo System is an adjunctive device used during TAVR and removed following completion of valve implantation. The ProtEmbo is an intra-aortic filter device that is designed to deflect embolic material arising during TAVR away from the cerebral circulation.
- Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
We turn exceptional individuals into funded founders. We back you first, then give you a bridge to Silicon Valley.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Information Technology
- Stage:Pre-Seed, Seed, Series A
- Geography: United Kingdom, United States, India
Investor stats
- Total investments: 283
- Round size: Seed $724k–$7M; Pre-Seed $55k–$3.1M; Series A $6M–$45M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Juno Bio — Disrupted vaginal microbiomes can cause everything from recurrent infections to infertility. Get your comprehensive vaginal microbiome test and find out where you stand.
- Sourcepulse — Your early warning system for software delivery (YC S23)
- EverSettled — Navigate the probate process with confidence. We provide a free checklist, guidance, and support to help families find clarity in the chaos of loss.
eCAPITAL is a venture capital investor that provides early to growth stage funding to technology and deep tech companies.
Show more...Investment focus
- Industry: Information Technology, Software, Manufacturing
- Stage:Series A, Series B
- Geography: Germany, United States, Italy
Investor stats
- Total investments: 123
- Round size: Series A $2.7M–$14M; Series B $3.1M–$27M
- Lead/follow: 69% lead, 31% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- VisioLab — Instantly scan products for self-checkout, using the iPad camera - no barcodes needed. Designed for speed, simplicity and human centricity.
- Dawnguard — AI-native platform for fast cloud design and implementation.
- QuoIntelligence — Our finished intelligence will significantly reduce your operational risks and allow you to make informed security decisions.
bmp Ventures is an innovative Venture Capital Company from Berlin. Since 1997 we’ve been investing Smart Money in Early Stage and Growth Startups. We finance ingenious business models with outstanding teams, who build fast-growing and sustainably profitable enterprises.
Show more...Investment focus
- Industry: Software, Information Technology, Manufacturing
- Stage:Seed, Series A
- Geography: Germany, United States, Austria
Investor stats
- Total investments: 120
- Round size: Seed $165k–$3.4M; Series A $30k–$5.9M
- Lead/follow: 40% lead, 60% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- Sedivention — Fight obesity within 20 minutes - fast, effective, long-term. A new weight-loss therapy for the treatment of obesity. Just a view minutes will change your life.
- Solar Materials — Solar Materials primarily engages in the development of technologies for the sustainable and economical recycling of solar modules.
- Litherm Technologies — Fully electric calcination as a pathway to zero-emission lime and cement production.
Impacting the future of medicine.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, The Netherlands
Investor stats
- Total investments: 208
- Round size: Series A $19M–$180M; Series B $16M–$155M; Series C $19M–$120M
- Lead/follow: 52% lead, 48% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- Azafaros — Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros.
- Inflazome — Situs gacor premium Megawin188 paling banyak di minati oleh semua kalangan karena pecah selayar tanpa henti dan memiliki tampilan yang sangat memanjakan mata.
- Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
Good Seed Ventures is a Venture Capital firm that exclusively invests in sustainable food tech.
Show more...Investment focus
- Industry: Food and Beverage, Food Processing, Biotechnology
- Stage:Seed, Series A, Pre-Seed
- Geography: Germany, Israel, United States
Investor stats
- Total investments: 33
- Round size: Seed $25k–$7M; Series A $7.5M–$50M
- Lead/follow: 15% lead, 85% follow
Portfolio highlights
- Lovely Day Foods — We harness the power of plants and cutting-edge technology to crack the egg.
- Libre Foods — MEAT, BUT MAKE IT MUSHROOMS. GET READY TO TASTE THE POWER OF FUNGI
- Nosh Biofoods — We create nutritional and highly functional proteins from non-GMO fungi. Our proprietary ferementation process is minimal, scalable, and sustainable.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!bm|t supports innovative and growth-oriented companies in Thuringia with equity investments and venture capital.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Seed, Series A
- Geography: Germany, United States
Investor stats
- Total investments: 70
- Round size: Seed $461k–$3.3M; Series A $1.1M–$10M
- Lead/follow: 60% lead, 40% follow
Portfolio highlights
- Altavo — Altavo operates as a medical device startup. Altavo harness the power of machine learning and state-of-the-art sensor technology to improve the lives of people who have lost their voice.
- Peeriot — Peeriot is a B2B software high-tech startup with a breakthrough in IoT. Peeriot offers a low-code software suite that simplifies IoT data sharing by tenfold.
- Influnate — Influnate is a tool that allows you to send and receive money via social media. Influnate enables users in social networks to “send and receive money easily, securely and quickly”. This can be done with a comment, a link, or via the Influnate web application. “Redirects to paid websites are a thing of the past,” said the startup.
EMBL Ventures invest throughout Europe with the aim to build companies that create significant commercial opportunities based on new therapeutic treatment.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: Germany, Austria, Ireland
Investor stats
- Total investments: 11
- Round size: Series A $3.9M–$15M; Series B $21M–$70M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- Arsanis — Arsanis is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. A deep understanding of the pathogenesis of infection, paired with access to some of the most advanced mAb discovery techniques and platforms available today, has positioned Arsanis to build andadvance a pipeline of novel mAbs with multiple mechanisms of action and high potency against their intended targets.The company’s lead clinical program, ASN100, is aimed at serious Staphylococcus aureus infections and is being evaluated in Phase 2 clinical trial for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients. In addition to ASN100, its preclinical pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus.Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with European research and preclinical development operations headquartered in Vienna, Austria (Arsanis Biosciences GmbH).
- Topas Therapeutics — Topas Therapeutics GmbH is a private Hamburg, Germany-based biotechnology company focused on developing products to address areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. The Topas Particle Conjugates technology platform induces antigen-specific immune tolerance by harnessing the liver’s naturalimmunology capabilities. The Company has several proprietary programs; lead product candidate TPM203 has recently entered clinical testing for pemphigus vulgaris, an orphan disease. Other programs are in anti-drug antibodies, celiac disease, Type 1 diabetes, as well as a multiple sclerosis program that is available for partnering.Topas has a research and option agreement with Eli Lilly and Company focused on antigen-specific tolerance induction and a multi-year agreement with Boehringer Ingelheim to collaborate in the field of anti-drug antibodies.Topas’ investors include: Epidarex Capital, Gimv, EMBL Ventures, Evotec and Boehringer Ingelheim Venture Fund.
- Crescendo Biologics — Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.
GENIUS Venture Capital is established on the initiative of the Federal State of Mecklenburg-Western Pomerania. It is a subsidiary of Technologie- und Gewerbezentrum e.V. Schwerin/Wismar. They fund innovation-driven technology companies in their startup or early growth stage. To date, GENIUS together with several private investors spent a totalof around 70 million euros on financing 25 companies.They are currently managing two venture capital funds on behalf of the Ministry of Economics, Employment and Health of the State Mecklenburg-Western Pomerania
Show more...Investment focus
- Industry: Software, Logistics, Health Care
- Stage:Seed, Pre-Seed
- Geography: Germany, Spain
Investor stats
- Total investments: 12
- Round size: Seed $509k–$7.1M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- SonoBeacon — SonoBeacon is an integrated software, hardware and platform solution provider. SonoBeacon's services enable companies to communicate directly with end users by delivering content to an end user's mobile device through ultrasound-based technology and interaction with a SonoBeacon-powered platform.
- Evertracker — Evertracker provides the first Neutral and Smart Control Tower for Global Supply Chains that enables manufacturers and producers to get end-to-end visibility and predictability of their global supply chains. The platform provides the transparency on an item level, which enables our users to not only know where their shipments are but what partswill be delayed or have issues. Thus they can plan their production more reliably.
- Innocent Meat — Innocent Meat turns food producer in cell-based meat producers by developing an automated end-to-end clean meat production system.
Investing early in Europe's most passionate founders.
Show more...Investment focus
- Industry: Health Care, Software, Financial Services
- Stage:Seed, Series A
- Geography: Germany, Austria, United Kingdom
Investor stats
- Total investments: 90
- Round size: Seed $1.2M–$7.7M; Series A $3.8M–$31M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — last raise in 2017
Portfolio highlights
- a2zebra — a2zebra is a zebra company that specializes in instructional technology for elementary school kids.
- Dermanostic — Dermanostic is an e-health app where patients receive a medical diagnosis and therapy recommendation for skin diseases.
- microsynetics GmbH — Developing hardware and software to help elderly people gaining more freedom and quality of life. Our first product is an emergency wristband which works together with an app, also connecting relatives via smartphone and phone integrated in the emergency wristband. The automated AI-based fall detection guarantees help even when the user - afteraccident - isn't capable anymore of activating the emergency call via integrated button.
With a track record of over 20 years in venture capital and experience from more than 200 investments in numerous companies BFB Brandenburg Kapital GmbH (BFB) is the most active equity investor in Brandenburg. BFB invests in fast-growing technology-orientated companies throughout the whole life-cycle. Target sectors are ICT/Digital Economy,Life Science, MedTech, Proptech, Industrial Applications. BFB invests in companies based in or with facilities in Brandenburg. The current VC fund is financed by the European Regional Development Fund (ERDF) an Investitionsbank des Landes Brandenburg (ILB).
Show more...Investment focus
- Industry: Health Care, Software, Information Technology
- Stage:Seed, Series A
- Geography: Germany, United Kingdom
Investor stats
- Total investments: 77
- Round size: Seed $823k–$6.1M; Series A $2.7M–$13M
- Lead/follow: 45% lead, 55% follow
Portfolio highlights
- Kupando — Kupando is a biopharmaceutical company that develops agonists to stimulates innate immunity.
- Captain T Cell — Captain T Cell is a start-up project that develops T cell-based immunotherapies for cancer patients. The company identifies novel high-efficiency TCRs for the development of T cell immunotherapies. It focuses on CMC- and preclinical development for their lead candidates.
- All About Accuracy — Sub-1mm accuracy and <1ms latency RF localization for physical AI. Train robots with ground-truth motion data cameras and GPS can't reach.
Simon Capital is an early-stage VC fund with €105M capital ready to invest in innovations that will improve our everyday lives, following the mission of investing “for the next generation”.
Show more...Investment focus
- Industry: Software, Biotechnology, Food and Beverage
- Stage:Series A, Seed, Series B
- Geography: Germany, Austria, The Netherlands
Investor stats
- Total investments: 22
- Round size: Seed $1.8M–$9.3M; Series A $1.7M–$14M; Series B $32M–$57M
- Lead/follow: 36% lead, 64% follow
- Last fund: Likely still investing — raised $123M in 2022
Portfolio highlights
- VisioLab — Instantly scan products for self-checkout, using the iPad camera - no barcodes needed. Designed for speed, simplicity and human centricity.
- Pacifico Biolabs — Pacifico Biolabs offers fermentation biotechnology for development, production and distribution of sustainable and food alternatives.
- dsb Deutsche Sanierungsberatung — dsb Deutsche Sanierungsberatung provides easy and sustainable solutions for climate-friendly homes energy-efficient renovations for homeowners.
Innovative post-revenue startups with first customers trust us as highly reliable investors. We have been an active player in the venture capital market for over 25 years. Due to our evergreen approach, we offer institutional venture capital without the limitations of the usual fund structure. Predominantly we invest straight equity. Additionally,we can offer venture debt to mature startups close to break-even in order to avoid further dilution for founders. Being a private investment company we act as both lead investor or co-investor. We can also fulfill the private lead investor role for public investors like Bayern Kapital. Together we are increasing YOUR company's value.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Series A, Series B
- Geography: Germany, Italy, United States
Investor stats
- Total investments: 118
- Round size: Series A $428k–$6.4M; Series B $732k–$21M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- socialhub — Boost your social media success with SocialHub. Manage channels, schedule posts & get meaningful analytics. Try it out now!
- TalentRocket — Talent Rocket is a job search engine that enables its users to find jobs with a suitable work environment for them. Job seekers can select their preferred company culture, follow their favorite companies, and start career conversations with employers. Talent Rocket was founded in 2014 and is based in London, United Kingdom.
- Goodly Innovations — Goodly Innovations is the leading regulated industry-focused global Pharma 4.0 provider for extended reality shop floor guidance. From cleanrooms to secondary packaging areas, labs and more, Goodly can help improve Pharma and BioPharma clients efficiency, OEE, quality, training and more
Seventure Partners is a French venture capital firm targeting in Tech/Digital and Life Sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with € 1 billion undermanagement as of December 31, 2023. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.The different funds/verticals on which Seventure Partners are focusing on today: - Life Sciences : Biotech, Healthcare, Nutrition - Tech/Digital : B2B SaaS, Fintech, Retailtech, Cybersecurity - Sports & Wellbeing - Blue Economy
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Series A, Series B
- Geography: France, United States, Germany
Investor stats
- Total investments: 247
- Round size: Series A $3.3M–$28M; Series B $3.4M–$63M
- Lead/follow: 36% lead, 64% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Ekstere — Ekstere facilitates selling and purchasing verified-quality used bicycles at a reasonable price.
- Pitchy — Create professional videos without technical expertise. Our online video editor helps you easily make business videos.
- Presto Engineering — We enable companies imagine and implement microelectronics solutions in high-value markets such as Industrial, Automotive, Communication and Medical.
Andera Partners, formerly known as Edmond de Rothschild Investment Partners (EdRIP) As heir to the traditions and values that have ensured the success of the Rothschild family for 250 years, the Edmond de Rothschild Group has established itself over time as a leading player in European finance. Its activities are grouped around two major areas:Private Banking and Asset Management. The Group offers wealthy families, entrepreneurs, and large institutions a full range of solutions combining a culture of tailored solutions, stability, performance, and innovation. The Edmond de Rothschild Group’s offering is characterised by strong convictions, with the desire to guarantee to each of its customers: A unique, close relationship, underpinned by the know-how and the variety of expertise of a large international group; Autonomous, experienced teams, who anticipate economic trends and innovate to establish long-term performance; The recognised stability, strength, and independence of a family-owned financial group. Founded by Baron Edmond de Rothschild in 1953, the Group has been chaired by his son, Baron Benjamin de Rothschild, since 1997.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Private Equity, Series A
- Geography: France, United States, Germany
Investor stats
- Total investments: 185
- Round size: Series A $7M–$83M; Series B $14M–$85M; Private Equity $110M–$237M
- Lead/follow: 42% lead, 58% follow
- Last fund: Likely still investing — raised $466M in 2022
Portfolio highlights
- Cyllene Therapeutics — EG 427 is a French biotechnology company that pioneers a new approach in gene therapy called pinpoint gene therapy.
- Inventiva Pharma — Inventiva Pharma is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology.They have built a pipeline backed by a discovery engine with an extensive library ofproprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging these assets and expertise, they are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.
- Rivermark Medical — Rivermark Medical develops a minimally-invasive treatment for Benign Prostatic Hyperplasia (BPH) that restores urinary function. Developed by urologists to reliably reduce BPH symptoms with minimal side effects.
S-Venture Capital Dortmund aims to fund technology companies and is a German regional investment group.
Show more...Investment focus
- Industry: Biotechnology, Guides, Genetics
- Stage:Series B, Series A
- Geography: Germany
Investor stats
- Total investments: 9
- Round size: Series B $3.6M–$9M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Innolume — Innolume is a semiconductor laser fab for GaAs quantum dot and quantum well diode lasers, serving photonics, research and industrial projects.
- Protagen — Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address anumber of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases.The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others.
- Scienion — Provider of advanced biotech instruments, specializing in precision microdispensing and solutions for single-cell and 3D cellular model sorting and isolation.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Amino Collective is an institutional venture capital firm investing at seed stage in health and bio companies. They help bring life-changing ideas to life by backing, connecting, and advancing our collective of entrepreneurs and scientists. The firm intends to invest in the sectors of biology, biotech, health tech, science, digital health, lifescience, and synthetic biology.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Artificial Intelligence
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 45
- Round size: Seed $2.4M–$14M; Pre-Seed $125k–$7.8M; Series A $12M–$37M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Calibre — Diagnostic testing, clinicians, and AI working together to help you deeply understand your health and how to improve it.
- Modern Relay — Modern Relay provides context graph for enterprise AI.
- Theorema — Autonomous R&D agents for biotech, pharma, chemicals, and materials. Theorema analyzes data, recovers R&D costs, and accelerates discovery. #1 on BixBench.
BlueYard backs founders building the interconnected elements that can become the fabric of our future.
Show more...Investment focus
- Industry: Software, Biotechnology, Blockchain
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, Germany, United Kingdom
Investor stats
- Total investments: 112
- Round size: Seed $1.2M–$14M; Pre-Seed $200k–$5.4M; Series A $7M–$47M
- Lead/follow: 40% lead, 60% follow
- Last fund: Likely still investing — raised $185M in 2022
Portfolio highlights
- Rapidata — Fast and reliable data labeling that powers your AI. Define your label needs now and get the results in minutes.
- Blockspace — Blockspace is an Ethereum infrastructure company operate out-of-protocol transaction pipelines.
- Blockspace — Connecting the world to Ethereum.
We invest in startups and VC funds that share our values across crucial sectors for the planet backed by a global network of entrepreneurs and scientists working towards a happier future
Show more...Investment focus
- Industry: Biotechnology, Food and Beverage, Life Science
- Stage:Series A, Seed, Series B
- Geography: Germany, United States, United Kingdom
Investor stats
- Total investments: 37
- Round size: Seed $2M–$9.3M; Series A $10M–$45M; Series B $8.7M–$61M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- Innovacell — Innovacell is a biotechnology firm entirely focused on the area of tissue engineering and it operates one of Europe's largest and most modern production facilities for the proliferation of the body's own tissue cells. Its supervisory board is chaired by the experienced financial expert, Dr. Harald Pöttinger, a director of Alpine EquityManagement AG, based in Bregenz, Austria. Innovacell currently employs 20 staff as well as numerous outside experts.
- Project Eaden — PROJECT EADEN combines pioneering technology and engineering expertise with an immense love for food and lust for life. For full indulgence. With zero guilt.
- Epoch Biodesign — Mellizyme Biotechnology is currently operating in stealth.
Grazia Equity is a venture Capital firm investing in innovative, technology driven startups with high potential.Based in Stuttgart (Germany), Grazia has been supporting a large number of mostly young companies, often from their foundation to the Initial Public Offering or eventual sale. In contrast to other venture capital firms, theypredominantly work with their own capital that they invest as entrepreneurs.
Show more...Investment focus
- Industry: Internet, E-Commerce, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: Germany, United States, Switzerland
Investor stats
- Total investments: 84
- Round size: Seed $1.1M–$8.2M; Series A $1.1M–$53M; Series B $4M–$59M
- Lead/follow: 35% lead, 65% follow
Portfolio highlights
- Q.ANT — Q.ANT develops photonic processors for AI and high-performance computing, utilizing light for information processing. The company also produces quantum sensors offering ultra-high magnetic field sensitivity in a compact form factor. These products aim to enable more intelligent and sustainable systems across various sectors like data centers,aerospace, and medical technology.
- XO Life — XO-Life.com is an online destination center. That provides services includes digital treatment monitoring and patient feedback R&D, marketing and sales. That offers services for Patient Insights, information exchange between patients and pharma, treatments and indications.
- Patronus Group — Rethinking elderly healthcare
96 Normal 0 false false false EN-GB X-NONE X-NONE
Show more...Investment focus
- Industry: Health Care, Medical Device, Medical
- Stage:Series A, Seed, Series B
- Geography: Germany, Finland, The Netherlands
Investor stats
- Total investments: 12
- Lead/follow: 8% lead, 92% follow
Portfolio highlights
- Fiagon — Fiagon develops clinical navigation systems that reimagine image guidance by improving the function of electromagnetic navigation. Fiagon's systems use electromagnetic tracking matrix algorithms and flexible pointer technology that indicates the position of the instrument used in the CT or MRI image data, allowing physicians to get accurateplanning, improve patient outcomes, and implementation of the operation.
- Xbird — xbird uses an AI-powered three-step process to provide patients with personalized therapy support and improve adherence
- SurgicEye — SurgicEye designs intra-operative imaging and instrument navigation solutions for surgical procedures. It offers a navigated radio-guided surgery based on the handheld 3-D freehand SPECT imaging technology called the declipse SPECT open surgery, an intraoperative 3D imaging system for invasive sentinel lymph node biopsy called the declipse SPECTLaparascopy, and a mobile SPECT imaging solution with a high resolution on a small footprint called the declipse SPECT imaging probe. The company also advises clients on medical device development, requirement engineering and software specification for medical devices, software development for medical devices, testing of software for medical devices, and support in the design and conduction of clinical studies.Dr. Jörg Traub founded SurgicEye in 2008, with its headquarters in Munich in Germany.
start-ups, SMEs, technology, co-investment
Show more...Investment focus
- Industry: Biotechnology, Health Care, Information Technology
- Stage:Pre-Seed, Seed
- Geography: Germany, The Netherlands, Austria
Investor stats
- Total investments: 22
- Lead/follow: no public data
Portfolio highlights
- Filuta AI — Operationalized Composite Artificial Intelligence
- Resistell AG — Resistell is a antibiotic resistance test.
- iThera Medical — Explore optoacoustic imaging technology for non-invasive in vivo visualization and quantification of disease-related tissue biomarkers.
Possible Ventures backs ambitious teams building frontier technology to positively impact society. We invest globally in the early stages, actively supporting founders via our collective of global entrepreneurs.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Pre-Seed, Series A
- Geography: Germany, United States, Australia
Investor stats
- Total investments: 170
- Round size: Seed $1.5M–$10M; Pre-Seed $586k–$3.5M; Series A $9.7M–$47M
- Lead/follow: 5% lead, 95% follow
Portfolio highlights
- Mkind — Mkind builds intelligent robots for high-mix manufacturing, developing advanced automation solutions that can adapt to diverse production requirements, improve operational efficiency, and support manufacturers in handling complex, low-volume, and frequently changing product lines.
- Orbem — Transform biological imaging with AI-powered MRI technology. Non-invasive solutions for poultry, fruits, nuts, and health. Building a sustainable future.
- Transition Metal Solutions — Transition harnesses wild microbial communities to recover copper and other critical metals from low-grade mining resources.
The German Federal Ministry of Research, Technology and Space (BMFTR) funds research programs, promotes in the fields of cutting-edge research, future technologies, innovation and space.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Grant, Seed, Series B
- Geography: Germany, United States, Canada
Investor stats
- Total investments: 64
- Round size: Seed $340k–$4.2M; Grant $294k–$11M
- Lead/follow: 61% lead, 39% follow
Portfolio highlights
- ChemInnovation — Molecules from Spectra - For a World without UnknownsAs ChemInnovation, we work on innovative & tailored AI-solutions for analytical chemistry. Within our first years as a company, we were able to bring our intelligent software METIS to researchers and partners within renowned chemical companies. Our smart software METIS accelerates theresearch and development of our customers. Therefore, it empowers them to accelerate their research, understand their chemistry and make their products safer. To achieve this, we have developed our own chemically inspired AI models and smart algorithms, which we now use to automatically evaluate complex data. We combine know-how from the chemical and computer science worlds thereby translating results from academia into productive cloud-software.
- Circus Group — At Circus, we believe cooking should be a loved hobby but not a daily necessity. Driven by the mission to fuel people's busy every day we are building a radically more convenient, sustainable, and affordable solution in food delivery. Circus was established in 2021 in Hamburg, Germany.
- Rock Tech Lithium — Rock Tech Lithium Inc. is a mineral exploration company focused on the lithium industry. Based in Vancouver and listed on the TSX Venture Exchange and the Frankfurt Stock Exchange, the Company’s international board of directors provides a truly global presence and offers unique access to capital and projects.The Company holds an interest in theGeorgia Lake lithium project in the Thunder Bay Mining District of Ontario. The Georgia Lake project consists of approximately 80 leases and approximately 20 claims covering approximately 4,590hectares. The project is located in an area underlain by metasediments and metavolcanics of Archaen age. The Georgia Lake pegmatites contain lithium-bearing spodumene. The spodumene-bearing pegmatites of the Georgia Lake area are located approximately 140 kilometers northeast of the city of Thunder Bay.
Seed Fonds has a strong competence network with national and international investors, business angels & expertes from the industry. They are specialized in the development of comprehensive financing models offering stability and development opportunities on the long term.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Seed, Series A
- Geography: Germany
Investor stats
- Total investments: 8
- Round size: Series A $2.2M–$6M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- miacosa — miacosa.de is operated by the Endorsed Goods GmbH. miacosa.de is a social shopping concept from Germany based in Cologne. Social Shopping the miacosa way means that members select their personal shopping team of experts and celebrities that present products they love on miacosa.de Miacosa is for members only. The free service starts with productsfrom the fields of Health Style, Home & Living, Kitchen and fashion accessories.
- Hemovent — Based in Aachen, Germany, Hemovent is a privately held medical technology company that is developing a portable ECMO (Extra Corporeal Membrane Oxygenation) unit. Hemovent was founded by serial entrepreneur, Christof Lenz and Oliver Marseille, inventors of the company’s proprietary platform. It is the goal of the company to develop aninnovative solution, with precision and craftsmanship, that will aide patients with lung and heart function while allowing them to be mobile.
- aquila biolabs — aquila biolabs is a German technology company focusing on the development of innovative laboratory devices for the analysis of shake-flask fermentations in biotechnological, chemical and pharmaceutical research and development.
Providing capital plus strategic, clinical, operational, financial, and commercial support to deliver the added value inventors seek.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Germany, United Kingdom
Investor stats
- Total investments: 26
- Round size: Series A $5.3M–$194M; Series B $5.3M–$45M; Series C $8M–$100M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely still investing — raised $1.2B in 2022
Portfolio highlights
- Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.
- Muna Therapeutics — Muna Therapeutics discovers and develops therapies that slow or stop neurodegenerative diseases such as alzheimer’s and parkinson's.
- HotSpot Therapeutics — HotSpot Therapeutics is a biotech startup that focuses on the development of allosteric therapies targeting regulatory sites on proteins. It develops a therapy platform to discover medicines and provide proper treatment to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspotstructures, harnessing the power of data science in its multidisciplinary approach to drug discovery, and helps patients to get treatment against several diseases.HotSpot Therapeutics was founded in 2017 and is headquartered in Boston, Massachusetts.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!We have been investing at the frontier of technology and science for over 30 years. We know what it takes to succeed.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Series B
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 93
- Round size: Series A $2M–$12M; Series B $5.1M–$30M
- Lead/follow: 41% lead, 59% follow
- Last fund: May invest from a new fund soon — raised $94M in 2016
Portfolio highlights
- AYOXXA — AYOXXA is a biotech company commercializing innovative technology developed at the National University of Singapore (NUS). AYOXXA’s patented technology platform is producing a new generation of biochips – merging biology with IT. This allows the biochip to accumulate large numbers of applications – measuring multiple protein markers for cancer,allergies, cardiovascular and infectious diseases – in a single test.
- Tacalyx — Tacalyx develops therapeutics targeting cancer-specific carbohydrate antigens on the surface of metastatic malignant tumors where no satisfactory treatments exist.The name Tacalyx is derived from TACA (Tumor Associated Carbohydrate Antigen) and ‘lyx’ from the term Glycocalyx, the glycan-containing layer covering cells. Cancer cells differ fromnormal cells by displaying aberrant carbohydrate structures on their surfaces promoting metastasis, angiogenesis or suppression of the immune system. TACAs result from the aberrant glycosylation that is seen with transformation to a tumor cell and represent attractive targets for cancer treatment since they are displayed with high cancer specificity and enhance tumor virulence via the mentioned diverse mechanisms.
- CryoTherapeutics — CryoTherapeutics is focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatment of coronary artery disease that causes heart attacks. The safety and efficacy of cryoenergy in the cardiovascular system has been demonstrated and CryoTherapeutics intendsto extend the benefits of cryoenergy to the problem of diseased coronary arteries.
At better ventures we invest in early-stage founders who aim to change our world for the better.
Show more...Investment focus
- Industry: Software, Food and Beverage, E-Commerce
- Stage:Pre-Seed, Seed, Series A
- Geography: Germany, Switzerland
Investor stats
- Total investments: 50
- Round size: Seed $1.1M–$6.9M; Pre-Seed $1.1M–$3.3M
- Lead/follow: 18% lead, 82% follow
Portfolio highlights
- Enzo — Enzo is a Heidelberg based InsurTech startup offering modern and smart insurance coverage for homeowners. Instead of just reacting to claims, Enzo takes a proactive customer-focused approach to prevent damages from happening at all. Thus, Enzo is leading a paradigm shift in a €100+ billion market that has barely improved customer experience forover 100 years. Our Goal is to become Europe's smartest homeowners insurance.
- Primogene —
- Tokura — Tokura focused on redesigning outpatient surgery (Ambulantes Operieren) through an integrated system of specialised facilities, experienced teams, and automated technology.
Delivery Hero - Always delivering an amazing experience.
Show more...Investment focus
- Industry: E-Commerce, Information Technology, Food Delivery
- Stage:Series A, Seed, Series B
- Geography: Singapore, Egypt, Brazil
Investor stats
- Total investments: 25
- Lead/follow: no public data
Portfolio highlights
- Charan — Charan is an operator of an e-commerce platform intended to sell second-hand fashion apparel.
- Qashier — Qashier provides smart point-of-sale solutions that help merchants digitize their businesses. Its flagship product is the Qashier Smart Terminal, a connected, multi-purpose device that combines a payments hub, powerful POS software, and a proprietary app store into one uniquely designed device. Qashier enables merchants to start, run, and growsuccessful stores with just one terminal on the counter. Qashier was founded in 2019 and is headquartered in Singapore.
- OneOrder — One Order delivers exceptional produce, custom cuts of meat, high-quality seafood, and imported foods offering an array of global flavors.
ERP Startfonds KfW finances and supports, among other things, business start-ups, small and medium-sized enterprises.
Show more...Investment focus
- Industry: Biotechnology, Pharmaceutical, Apps
- Stage:Series B, Series A
- Geography: Germany, United States
Investor stats
- Total investments: 6
- Lead/follow: no public data
Portfolio highlights
- tolingo — tolingo is one of the most renowned and successful translation agencies in Germany – a fact which motivates us in our work across every division of our company every day and helps drive us to constantly improve the services we offer to our clients. A human touch is crucial, whether in terms of our employees’ respectful, open interaction with oneanother at our headquarters in Hamburg, our consultations and service meetings with our clients, or the close, productive working relationships we enjoy with our specialist translators and industry experts all over the world. We strive for collaborative success and partnerships on equal footing without losing sight of the expectations we’ve set for ourselves or the standards and goals we’re determined to meet. This is how we’ve been able to transform from a little translation agency into a globally present provider with a sophisticated portfolio of services – with market-leader status in our sights.
- Rodos BioTarget — Rodos BioTarget (RBT) is a biopharmaceutical company developing a targeted drug delivery platform. RBT’s patented TargoSphere® technology enables carrying a broad range of active agents selectively into the center of the immune response - i.e., directly into antigen-presenting cells.RBT currently applies its TargoSphere® technology successfullyin various models of infectious diseases caused by viruses like HCV/ Hepatitis C and HIV/ AIDS and by bacteria like in Tuberculosis, Legionellosis, and MRSA. Yet, any disorder that goes along with either overshooting or insufficient immunity caused by antigen-presenting cells - like chronic inflammations, cancers, allergies, and autoimmune diseases - may be addressed by RBT’s TargoSphere® technology.
- Intelligent Apps — In 2009 founders Niclaus Mewes and Sven Kuelper launched "mytaxi" - the first taxi app with a direct connection between passenger and driver. mytaxi has grown to the fastest growing taxi-app with more than 7 million downloads and 35.000 connected taxis. mytaxi is available in over 40 German cities as well as Washington, Madrid, Barcelona,Warsaw, Vienna, Graz, Salzburg and Zurich. Investors include T-Venture Holding GmbH (Deutsche Telekom AG), Daimler Mobility Services GmbH (Daimler AG), KfW, e42 GmbH and Lars Hinrichs (Cinco Capital GmbH).mytaxi brings a demand for quality to the taxi service for the first time. Every driver using mytaxi has the ability to become a contractor and build their own client base by consistently providing passengers with good service and earning high customer ratings. Through the given peer-to-peer connection between passenger and driver the whole ordering process becomes very transparent for both. The passenger can not only track the taxi’s arrival in the app but also see which driver is coming. For the driver the cost modell is very attractive as they only pay for a successfully completed trip.The aim of mytaxi is to drive the concept of urban mobility and to further strengthen its position as an international leader in this field. Accordingly to that mytaxi took over the app development services for Daimler Mobility Services GmbH (Daimler AG).
Think.Health invests as a boutique risk-taker in healthcare ventures. We continuously seek innovations and disruptive business models in digital healthcare, medical technologies and health service providers,
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Seed, Series A, Series B
- Geography: Germany, United States, France
Investor stats
- Total investments: 36
- Round size: Seed $1.1M–$8.7M; Series A $3.6M–$28M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Robeaute — Redesigning the future of neurosurgery by creating the new standard device that will provide surgeons with seamless access to delicate areas of the brain parenchyma and with real-time data.
- Inflammatix — Inflammatix develops rapid point of care diagnostic tests by reading the immune system, and resolves major clinical health challenges.
- Sphingotec GmbH — Improving patient outcomes with innovative diagnostics for critical care: Actionable insights in real-time
TVM Capital Life Science is one of the transatlantic Venture Capital pioneers with teams based in North America and Europe.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series B, Series C
- Geography: United States, Germany, United Kingdom
Investor stats
- Total investments: 102
- Round size: Series B $7.5M–$50M; Series C $10M–$55M
- Lead/follow: 19% lead, 81% follow
- Last fund: May invest from a new fund soon — raised $290M in 2005
Portfolio highlights
- Definiens — Definiens is the provider of image analysis and data mining solutions for quantitative digital pathology in the life sciences, diagnostic biomarkers and healthcare industries. Definiens software provides detailed readouts from whole tissue slides, cell-based assays and full body scans and allows correlating this information with data derived fromother sources. By automating analysis workflows, Definiens helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and supports better decisions in research, diagnostics and therapy. Definiens’ vision is to open new fields of research, to contribute to development of personalized medicine and to significantly improve the quality of patients’ lives. Definiens is headquartered in Munich, Germany, and has offices throughout the United States.
- Lamab Biologics — Lamab Biologics operates as a biotechnology company. Lamab Biologics develop first-in-class monoclonal antibody prophylactic therapeutic targeting IgE, a key mediator for allergic diseases.
- Rapid Micro Biosystems — Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to RapidMicro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.
Global Asset Fund is a private equity firm based in Germany that finances early and later stage venture investments. The fund enables the development of products and technologies that address a growing market of tomorrow.
Show more...Investment focus
- Industry: Medical, Therapeutics, Biotechnology
- Stage:Series A, Series B
- Geography: Germany
Investor stats
- Total investments: 8
- Round size: Series A $1M–$1.9M; Series B $1.6M–$2.9M
- Lead/follow: 13% lead, 87% follow
Portfolio highlights
- Siltectra — SILTECTRA is a high-tech company specializing in kerfless wafering and thinning, an innovative new technology for manufacturing wafers. Kerfless wafering by SILTECTRA is a platform technology which can be used in a wide variety of industries and for many different materials.
- Isarna Therapeutics — Isarna Therapeutics has an unmatched commitment to developing selective TGF-β inhibitors to effectively treat ophthalmic diseases. They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.
Collaboration with outstanding initiators with exceptional insights, from inception through all levels of progress. Lima Ventures supports visionary founders as well as provides certain services to early startups. We seek innovative technology-driven entrepreneurs who generate and lead companies that will inspire millions.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, FinTech
- Stage:Seed, Pre-Seed
- Geography: Turkey, United Kingdom, Estonia
Investor stats
- Total investments: 32
- Lead/follow: no public data
Portfolio highlights
- Shippn — International package forwarding service. Shop from Amazon, Shein, Macy's worldwide. Fast shipping with DHL & FedEx. Trusted by 50,000+ customers.
- heybooster — Heybooster is a provider of analytical tools to ecommerce companies to take better digital marketing decisions.
- Mars Studios — Mars Studios is an experienced team of growth hackers & marketers that can help you to increase your revenue. Rocket Your App to Success: Mars Studios
VF-Funds for innovative and scalable start-ups from the Rhineland Area, Germany
Show more...Investment focus
- Industry: Software, Health Care, Manufacturing
- Stage:Seed, Series A, Pre-Seed
- Geography: Germany, Spain
Investor stats
- Total investments: 27
- Lead/follow: no public data
Portfolio highlights
- IonKraft — IonKraft's barrier coating technology for plastic packaging, offers excellent product protection while being 100% recyclable.
- Eeden — Eeden engages in the manufacture and supply of textiles.
- Planted Green — Planted Green plants mixed forests to compensate for CO2 emissions.
We are the home for entrepreneurs with a big vision who want to create something less ordinary. Something that matters. For all of us.
Show more...Investment focus
- Industry: Health Care, Software, Information Technology
- Stage:Seed, Series A
- Geography: Germany, United Kingdom, Finland
Investor stats
- Total investments: 66
- Lead/follow: no public data
Portfolio highlights
- Elio — Putting leading scientific data into context, to enable others to respond to climate change’s dynamism and act on solutions with confidence.
- Ocean Ledger — Precision analytics to design, implement & monitor coastal mitigation and adaptation.
- NatureMetrics — NatureMetrics is the World-Leading provider of Biodiversity monitoring data, using eDNA surveys, metabarcoding & more. Book your demo today!
Biotech Investor funding in Germany at a glance
Stats across 870 deals from 979 investors.
Access all 979 investors in Germany Biotech startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotech Investors in Germany investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 979 investors investing in Germany Biotech startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!